MedTrace Logo

The CoPenHagen PREeClampsia and cardIOvascUlar diSease Study

NCT03949829 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 921

Last updated 2022-12-12

No results posted yet for this study

Summary

Women with a history of preeclampsia (PE) have increased risk of hypertension and cardiovascular disease (CVD) later in life. Thus, PE is acknowledged as an independent risk factor for CVD, which is the number one cause of death in women in the western part of the world.

Objective:

The purpose of this study is to investigate 1) the prevalence of CVD after PE, 2) which women have the highest risk of developing CVD, 3) when early stages of CVD can be detected in women with previous PE and 4) how CVD progress over time.

Methods:

1000 women with previous PE between the age of 35-55 years will be invited to participate in a follow-up study consisting of anthropometric measurements, blood pressure measurement, urine- and blood samples, cardiac CT-scan and questionnaires. Coronary atherosclerosis will be evaluated using CT imaging.The women will be compared with women with a formerly uncomplicated pregnancy,

Summary:

The study will provide new important information to guide future clinical follow-up, and potentially prevent disease and early death in a large group of women with a history of PE.

Conditions

Interventions

DIAGNOSTIC_TEST

Cardiovascular CT

Cardiac and cardiovascular non-contrast and contrast CT

Sponsors & Collaborators

  • Herlev Hospital

    collaborator OTHER

  • Klaus Fuglsang Kofoed

    lead OTHER

Principal Investigators

  • Peter Damm, MD, DmSc · Department of Obstetrics, Rigshospitalet, University of Copenhagen, Denmark

Eligibility

Min Age
35 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-20
Primary Completion
2020-03-30
Completion
2031-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03949829 on ClinicalTrials.gov